EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial

Eugene R Viscusi iD, Oscar de Leon-Casasola iD, Jesús Cebrecos iD, Adam Jacobs iD, Adelaida Morte iD, Esther Ortiz iD, Mariano Sust iD, Anna Vaqué iD, Ira Gottlieb iD, Stephen Daniels, Derek Muse, Michael E Kuss iD und 3 weitere

Pain Practice · 2024

DOI: 10.1111/papr.13399 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pain Practice, 2024. Verfasst von Eugene R Viscusi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Celecoxib, Tramadol, Postoperative Pain, Analgesics, Opioid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the randomized, phase 3, SUSA‐301 trial, celecoxib‐tramadol co‐crystal (CTC) provided significantly greater analgesia compared with celecoxib, tramadol, or placebo in adults with acute, moderate‐to‐severe, postoperative pain. This post hoc, secondary analysis further evaluated the use of rescue medication and the incidence of treatment‐emergent adverse events (TEAEs).

Methods

Patients ( N = 637) were randomized 2:2:2:1 to receive oral CTC 200 mg twice daily (BID; n = 184), tramadol 50 mg four times daily (QID; n = 183), celecoxib 100 mg BID ( n = 181), or placebo QID ( n = 89). Post hoc analyses were conducted on the use of rescue medications up to 4 and 48 h post‐study drug dose, stratified by baseline pain intensity (moderate/severe), and on the incidence of TEAEs, stratified by rescue medication use.

Results

A significantly lower proportion of patients received any rescue medication within 4 h post‐study dose with CTC (49.5%) versus tramadol (61.7%, p = 0.0178), celecoxib (65.2%, p = 0.0024), and placebo (75.3%, p = 0.0001); this was also seen for oxycodone use. Fewer patients in the CTC group received ≥3 doses of rescue medication compared with the other groups, irrespective of baseline pain intensity. In patients who did not receive opioid rescue medication, CTC was associated with a lower incidence of nausea and vomiting TEAEs versus tramadol alone. In patients who received rescue oxycodone, the incidence of nausea was similar in the CTC and tramadol groups, and higher versus celecoxib and placebo.

Conclusion

Celecoxib‐tramadol co‐crystal was associated with reduced rescue medication use and an acceptable tolerability profile compared with tramadol or celecoxib alone in adults with acute, moderate‐to‐severe, postoperative pain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CelecoxibTramadolPostoperative PainAnalgesics, OpioidPain MeasurementOsteotomyHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultAgedBunionCyclooxygenase 2 Inhibitors

Stichwörter der Autor:innen

acute painanalgesiaanti‐inflammatory agents—non‐steroidalcelecoxibco‐crystaljoint painpostoperative paintramadol

Substanzen

CelecoxibTramadolAnalgesics, OpioidCyclooxygenase 2 Inhibitors

Autor:innen und Institutionen

  • Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • University of Buffalo/Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Esteve Pharmaceuticals S.A., Barcelona, Spain.
  • Premier Research, Reading, UK.
  • Chesapeake Research Group LLC, Pasadena, Maryland, USA.
  • Optimal Research LLC, Austin, Texas, USA.

ORCID-Profile: Eugene R Viscusi, Oscar de Leon-Casasola, Jesús Cebrecos, Adam Jacobs, Adelaida Morte, Esther Ortiz, Mariano Sust, Anna Vaqué, Ira Gottlieb, Michael E Kuss, Sebastián Videla, Neus Gascón, Carlos Plata-Salamán

Zitieren

APA

Viscusi, E. R., de Leon-Casasola, O., Cebrecos, J., Jacobs, A., Morte, A., Ortiz, E., Sust, M., Vaqué, A., Gottlieb, I., Daniels, S., Muse, D., Kuss, M. E., Videla, S., Gascón, N., & Plata-Salamán, C. (2024). Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial. Pain Practice. https://doi.org/10.1111/papr.13399

Vancouver

Viscusi ER, de Leon-Casasola O, Cebrecos J, Jacobs A, Morte A, Ortiz E, et al. Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial. Pain Practice. 2024. doi:10.1111/papr.13399

BibTeX
@article{Viscusi2024,
  author = {Viscusi, Eugene R and de Leon-Casasola, Oscar and Cebrecos, Jesús and Jacobs, Adam and Morte, Adelaida and Ortiz, Esther and Sust, Mariano and Vaqué, Anna and Gottlieb, Ira and Daniels, Stephen and Muse, Derek and Kuss, Michael E and Videla, Sebastián and Gascón, Neus and Plata-Salamán, Carlos},
  title = {Celecoxib‐tramadol co‐crystal in patients with moderate‐to‐severe pain following bunionectomy with osteotomy: Secondary analyses by baseline pain intensity and use of rescue medication of a phase 3, randomized, double‐blind, factorial, active‐ and placebo‐controlled trial},
  journal = {Pain Practice},
  year = {2024},
  doi = {10.1111/papr.13399}
}
Kostenlos starten →